Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Giant Cell Tumor of Bone: later-stage trial registry
2 of 4 indexed Giant Cell Tumor of Bone trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Giant Cell Tumor of Bone: 4 US clinical trials tracked, 2 recruiting.
Giant Cell Tumor of Bone is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is St. Louis University, running 1 of these trials.
Enrollment posture brief
Registry condition giant-cell-tumor-of-bone
OPEN 2 | RECR 50% | LATE 2 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Giant Cell Tumor of Bone lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Giant Cell Tumor of Bone on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Giant Cell Tumor of Bone is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
PROMIS and Mobility Evaluation in Sarcoma Patients
University of Calgary
NCT07227961
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
St. Louis University
NCT03295981
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
NCT03449108
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
Amgen
NCT03301857
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Giant Cell Tumor of Bone records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Giant Cell Tumor of Bone trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Giant Cell Tumor of Bone page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Giant Cell Tumor of Bone trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- St. Louis University sponsors the most Giant Cell Tumor of Bone trials on record, review their full trial history before evaluating a specific study. See St. Louis University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Giant Cell Tumor of Bone condition card totals 4 registered trials; most-linked intervention Autologous Tumor Infiltrating Lymphocytes LN-145-S1; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.